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ABSTRACT
Objective: Omeprazole magnesium is indicated for the treatment of erosive esophagitis associated with gastroesophageal reflux disease. It is one 
of the highly prescribed proton pump inhibitor in the management of peptic ulcer diseases. The therapeutic concentration of a drug in blood can 
be maintained for a prolonged period of time by administering it in the form of in situ floating gel dosage form. Omeprazole magnesium undergoes 
degradation at a low pH of the esophagus and stomach; it is therefore given as in situ gel, so, there is minimum contact with acidic pH.
Methods: Omeprazole magnesium suspension prepared using various polymers and floating agents in varying concentrations. Several evaluation 
tests including dissolution test to ensure the release of the drug from formulation by in vitro technique, color and homogeneity, in vitro floating 
duration, in vitro gelling capacity, drug content determination, pH of the formulation, and floating lag time were studied.
Results: All formulations demonstrated good Fourier-transform infrared compliance and no interaction between drug, polymer, and other excipients. 
The study’s findings show that the formulation F6 showed the best results.
Conclusion: The developed formulation was a viable alternative conventional solution by virtue of its ability to enhance bioavailability through 
its longer gastric residence time and ability to sustain drug release as well as the advantage of floating and pH which minimize the degradation of 
omeprazole magnesium which is easily degraded by acidic environment.
Keywords: In situ gel, Gastroesophageal reflux disease, omeprazole magnesium, Polymers, In vitro floating duration, In vitro gelling capacity 
bioavailability, Gastric resident time.
INTRODUCTION
Floating systems are low-density systems with sufficient buoyancy to 
float over the gastric contents without affecting the gastric emptying 
rate for a prolonged period of time. While the system is floating on the 
gastric contents, the drug is released slowly at the desired rate from the 
system [1].
Floating system results in an increased gastric retention time and 
a better control of the fluctuations in plasma drug concentration. 
Minimal gastric content is required to allow proper achievement of the 
buoyancy retention principle and a minimal level of floating force (F) is 
also required to keep the dosage form reliably buoyant on the surface 
of the meal. Formulation of gastro retentive in situ gel system involves 
the use of gelling agent which can form a stable sol/suspension system 
to contain the dispersed drug and other excipients. The gelling of this 
sol/suspension system is achieved in gastric environment, triggered by 
ionic complexation due to change in pH [2].
Gastroesophageal reflux is the involuntary movement of gastric 
contents to the esophagus (Fig. 1). Gastroesophageal reflux is a 
normal physiological process that occurs several times a day without 
symptoms or damage of the esophageal mucosa in most otherwise 
healthy individuals. Gastroesophageal reflux disease is a condition in 
which reflux of gastric contents into the esophagus produces frequent 
or severe symptoms that negatively affect the individual’s quality of life 
or result in damage to esophagus, pharynx, or the respiratory tract [3].
Omeprazole magnesium (Fig. 2) is a benzimidazole with selective and 
reversible proton pump inhibition activity. It forms a stable disulfide 
bond with the sulfhydryl group of the hydrogen-potassium (H+ - K+) 
ATPase found on the secretory surface of parietal cells, thereby 
inhibiting the final transport of hydrogen ions (through exchange 
with potassium ions) into the gastric lumen and suppressing gastric 
acid secretion [4].
METHODS
Omeprazole magnesium was kindly provided by Dr Reddy’s 
Laboratories, Hyderabad, sodium carbonate sodium alginate, methyl 
paraben, and propyl paraben were procured from Arora and company, 
Delhi, Sodium citrate and Hydrochloric Acid form Central Drug House 
(P) Ltd., New Delhi, Calcium chloride from Loba Chemicals, Mumbai. All 
chemical and reagents used were of analytical grade. De-ionized water 
was used for the complete study.
Preformulation studies
Preformulation studies required to ensure the development of a 
stable as well as therapeutically effective and safe dosage form. These 
studies focus on the physicochemical properties of the drug that 
could affect performance and development of an efficacious dosage 
form.
Description of drug
Organoleptic properties of drug, that is, color, odor, and taste were 
observed.
Identification of drug
•	 UV spectrophotometric analysis of drug
 Ultraviolet absorption in the range 200–400 nm of a 100 μg/ml 
solution of the drug in 0.1 N HCl was determined [5].
•	 Fourier-transform infrared (FTIR) analysis of drugs
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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 The FTIR analysis of the sample was carried out for qualitative 
compound identification in ATR based Brukers Tensor 27 
instrument. The samples were kept at room temperature 
(initially) and at 50°C for 15 days before study.
Analytical estimation of drug
•	 Determination of absorption maxima (λ max)/wavelength 
maxima
 The standard stock solution of omeprazole magnesium was 
prepared by dissolving 10 mg of drug in 0.1N HCl in 100 ml 
volumetric flask. Stock solution of omeprazole magnesium was 
further diluted in 0.1 N HCl to get standard solution of 100 μg/
ml. The resulting solution was then scanned between 200 and 
400 nm UV visible spectrophotometer (shimadzu 1700).
•	 Preparation of standard calibration curve of Omeprazole 
magnesium Omeprazole magnesium (10 mg) was dissolved in 
(0.1 N HCl, pH 1.2) and volume was made up to 100 ml in 100 ml 
volumetric flask. This solution (100 μg/ml) was further diluted 
with (0.1 N HCl, pH 1.2) to obtain solution of 10–50 μg/ml. The 
absorbance of each solution was measured at λmax 348.5 nm 
using UV spectrophotometer. The standard curve was obtained 
by plotting absorbance versus concentration (μg/ml).
•	 Melting point determination
 Melting point of omeprazole magnesium was determined using 
melting point apparatus. The pre-sealed capillary filled by the 
small amount of drug, the capillary, and thermometer placed in 
melting point apparatus. The temperature noted when the drug 
starts to melt and till complete melt. The standard melting point 
is between 199 and 201°C (USP, 2005).
•	 Solubility determination
 For quantitative solubility studies, known amount of drug 
(10 mg) was suspended in solvents, that is, water, 0.1 N 
HCl. The solutions were stirred for 48 h on magnetic stirrer 
under thermostat. To separate phases, the solutions were 
left to sediment for 24 h under thermostat circumstances. 
The absorption of diluted aliquots was measured with UV 
spectrophotometer [6,7].
•	 Drug-polymer compatibility study
 The possible interaction between the drug and excipients was 
studied by infra-red spectroscopy. The equal quantity of drug and 
excipient was kept at 50°C for 15 days and the same quantity of 
both to prepare fresh immediate samples was taken and spectra 
were observed for compatibility [8].
Formulation and evaluation of in situ gel
Fabrication of omeprazole magnesium in situ gel
Omeprazole magnesium suspension prepared using various polymers 
and floating agents. Sodium alginate solution of different concentrations 
(0.50–1.5 g) prepared in deionized water containing sodium citrate 
(0.25 g) and calcium chloride (0.016 g). The sodium alginate dispersed 
in deionized water, heated up to 90°C with stirring continuously on 
magnetic stirrer and then cooled below 40°C various concentrations of 
calcium carbonate and drug was added after cooling the solution below 
40°C with continuous stirring to form uniform dispersion. Total nine 
formulations (Table 1) were prepared and evaluated [9].
Evaluation and characterization of floating in situ gel
Physical appearance
Sodium alginate based in situ suspension was visually checked for their 
clarity, that is, color, homogeneity.
pH of in situ solution
The pH was measured for sodium alginate based in situ suspension 
using a pH meter. The pH of each suspension was determined in 
triplicates.
In vitro gelling capacity
To evaluate the formulations for their in vitro gelling capacity by visual 
method, suspension of in situ gel forming drug delivery system was 
prepared. The in vitro gelling capacity of formulations was measured by 
Table 1: Formulae of formulation
Formulation code Ingredient 
F1 F2 F3 F4 F5 F6 F7 F8 F9
Omeprazole magnesium (g) 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100 0.100
Sodium alginate (g) 0.50 1.0 1.5 0.50 1.0 1.5 0.50 1.0 1.5
Tri-sodium citrate (g) 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
Calcium chloride (g) 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016 0.016
Calcium carbonate (g) 0.25 0.25 0.25 0.75 0.75 0.75 1.5 1.5 1.5
Methyl paraben (g) 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18
Propyl paraben (g) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2
Water q.s. (ml) 50 50 50 50 50 50 50 50 50
Fig. 1: Gastroesophageal reflux disease
Fig. 2: Structure of omeprazole magnesium
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placing 5 ml of the gelation solution (0.1 N HCl) in a 15 ml borosilicate 
glass test tube and maintained at 37±1°C temperature. 1 ml of 
formulation suspension was transferred slowly by placing the pipette 
at surface of fluid in test tube. As the suspension comes in contact with 
gelation solution, it immediately converted into stiff gel like structure. 
The gelling capacity of solution was evaluated on the basis of stiffness 
of formed geland time period for which formed gel remains as such. The 
in vitro gelling capacity was graded in three categories on the basis of 
gelation time and time period for which formed gel remains [10].
(+) Gels after few minutes, dispersed rapidly, (++) Gelation immediate 
remains for 12 h, (+++) Gelation immediate remains for more than 12 h.
In vitro floating duration
The in vitro floating study was determined using USP dissolution 
apparatus II having 900 ml of Hydrochloric acid (0.1 N). The temperature 
of the dissolution medium was kept at 37°C and 10 ml prepared in situ 
gel formulations were transferred. Time for the formulation took to 
emerge on the medium surface (floating lag time) and the time the 
formulation constantly floated on the dissolution medium surface 
(duration of floating) was noted.
Floating lag time
The floating lag time is defined as time taken by the gel to reach the top 
from bottom of the dissolution flask. The floating lag time is determined 
by visual inspection in a USP (Type II) dissolution test apparatus 
containing 900 ml of 0.1 N HCl at 37°C.
Determination of drug content
The 5 ml of the suspension was added to 100 ml (0.1N HCl, pH 1.2) 
solution and stirred for an hour on magnetic stirrer. The suspension was 
filtered and the drug concentration was determined using UV-visible 
spectrophotometer at λmax 348.5 nm against a suitable blank solution [11].
In vitro drug release study
The release of omeprazole magnesium from sustained release 
suspension was determined using dissolution apparatus I (basket 
covered with muslin cloth) at 50 rpm. The rotation speed was slow 
enough to avoid breaking of gelled formulation and maintained at 
mild agitation conditions as remains at in vivo. The 900 ml dissolution 
medium of 0.1N HCl was maintained at 37°C±0.5°C temperature. 
A sample (5 ml) of solution was withdrawn from the dissolution 
apparatus at 0 min, 15 min, 30 min, 45 min, 60 min, 1 h, 2 h, 3 h, 4 h, 5 h, 
6 h, 8 h, 10 h, and 12 h of dissolution. The samples were filtered through 
Whatman filter paper and analyzed using UV method. Cumulative 
percentage of drug release was calculated [2].
Selection of best formulations
On the basis of various evaluation parameters, namely floating lag 
time and in vitro release study two formulations were found to be 
optimum for the further study, that is, F3 and F6. These formulations 
were formulated and evaluated for physical appearance, pH of in situ 
solution, drug content, in vitro floating duration, floating lag time, 
and in vitro drug release study of the formulations. On the basis of 
dissolution, F3 was found to be having less drug release as well as 
drug content as compared to F6, thus F6 was selected as the final 
formulation.
Study of marketed formulation and its comparison with final 
formulation
OMEZ Insta 20 mg by Dr. Reddy’s was the available marketed 
preparation. This product was taken as the standard and was compared 
with the final formulation with respect to evaluating parameters, 
namely, in vitro drug release, drug content, release kinetics, similarity 
factor, and difference factor.
Drug content uniformity
The entire sachet was dissolved in 100 ml 0.1 N HCl and kept for 2 h. 
The solution was filtered and filtrate (5 ml) was diluted to 10 ml. 
Absorbance of the resulting solution was measured with a UV-Visible 
spectrophotometer UV-1700 (Shimadzu, Japan) at λmax 348.5 nm.
In vitro drug release
A USP dissolution apparatus type II was employed to study in vitro 
drug release. The dissolution medium used was 900 mL of 0.1N HCl, 
37 ± 0.5°C temperature at stirring rate 50 rpm.
Kinetic modeling
Model independent methods
A simple model independent approach uses a difference factor (f1) and 
a similarity factor (f2) to compare dissolution profiles.
a) Difference factor
 The difference factor calculates the percentage difference 
between the two curves at each time point and is a measurement 
of the relative error between the two curves. Reference values 
are given in Table 2. It is calculated by formulae:
𝑓1 = Σ(Rt-Tt)/Σ𝑅𝑡 ×100
b) Similarity factor
 The similarity factor is a logarithmic reciprocal square root 
transformation of the sum of squared error and is a measurement 
of the similarity in the percentage dissolution between the two 
curves, that is, test - reference. It represents closeness of two 
comparative formulations. Reference values are given in Table 2. 
It is calculated by formulae:
Model dependent methods
Model dependent methods are based on different mathematical 
function, which describes the dissolution profile. The dissolution 
profiles are evaluated depending on the derived model parameters. The 
model dependent approach included zero order, first order, Higuchi, 
and Korsmeyer–Peppas model.
Release kinetics described the overall release of the drug from the 
dosage forms. As qualitative and quantitative changes in a formulation 
may alter drug release and in vivo performance, developing tools 
that facilitate products development by reducing the necessity of 
bio-studies is always desirable. In this regard, the use of in vitro drug 
dissolution data to predict in vivo bio-performance can be considered 
as the rational development of controlled release formulations.
Data obtained from the in vitro release studies were fitted to various 
model dependent kinetics equations such as zero order, first order, 
Higuchi model, and Korsmeyer–Peppas model which are shown below.
Zero order model Qt =  Qo +Kot
First order model log C =  log Co –Kt/2.303
Higuchi model Q =  KH × t½
Korsmeyer–peppas model Q/Qo = Ktn
Where, Ko to KH were release rate constants, Q/Qo was fraction of drug 
released at time t, K was a constant and n was diffusion constant that 
indicates general operating release mechanism. For Fickian (diffusion 
controlled), n ≤ 0.5; for non Fickian release, “n” value is in between 0.5 
Table 2: Comparison of dissolution profiles
f1 f2 Inference
0 100 Dissolution profiles are identical
≤15 ≥50 Similarity or equivalence of two profiles
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to 1.0; for zero order release, n= 1; for super case transport II, n>1.040. 
Based on the slope and the r2 values obtained from the above models 
the mechanism of drug release was decided [12,13].
RESULTS AND DISCUSSION
Preformulation studies
Description of drug: The observed parameters are reported in Table 3.
Identification of drug
a) UV spectrophotometric analysis of drug
 Photometric spectrum shows by data analysis that the there is only 
one significant peak which is clearly distinguishable and obtained 
at 348.5 nm. Hence, absorption maxima (λmax) of omeprazole 
magnesium are meant to be 348.5 nm.
b) FTIR spectrum method
 Drug and polymers identified by IR spectrum method which are 
compared with its standard IR given in pharmacopeia. These IR 
spectra given below (Table 4) shown that the peaks obtained in these 
spectra (Fig. 4) are similar to that given in standard (Fig. 3).
Analytical methods of estimation
Analytical methods obey Beer’s law and found suitable for the study. 
Standard calibration curve of omeprazole magnesium was prepared in 
0.1 N HCl.
Determination of absorption maxima (λmax)/wavelength maxima
The λmax of given sample of omeprazole magnesium (348.5 nm) 
and standard value (345.42 nm) found to be similar hence drug is 
omeprazole magnesium.
Preparation of standard calibration curve of omeprazole magnesium
The standard curve was obtained by plotting absorbance versus 
concentration (μg/ml; Table 5).
Solubility determination
Omeprazole magnesium was very slightly soluble in water (1 mg in 
100 ml), readily soluble in 0.01 N HCl (10 mg in 100 ml).
Melting point determination
Melting point of omeprazole magnesium was found to be in the range 
of 199–201°C.
Table 3: Description of drug




Table 4: Interpretation of infrared spectrum of omeprazole 
magnesium
S. No Peaks (cm-1)
Absorbance assignment Reported Observed
1 C= C aromatic stretching 1591 1591
2 methyl C-H stretching 2944 2931
3 out of plane bending of aromatic 
ring bonds
850 843.97
4 symmetrical C-H bending 1410 1412.35
5 symmetrical C-H bending 1477 1483.15
6 -C-O-C- asymmetrical stretching 1034 1065.56
7 strong –S= O stretching, 1014 1011.22




FTIR spectrum shows the peaks of pure drug sample and polymers 
as compared to standard drug samples, that is, no chemical reaction 
occurs between polymers and drug samples (Table 6).
Evaluation of prepared in situ gels
The color, homogeneity, pH, gelling capacity, floating time, floating lag 
time, and drug content observed are as following in Table 7.
Fig. 3: Standard Fourier-transform infrared spectrum of 
omeprazole magnesium (reference)
Fig. 4: Fourier-transform infrared of omeprazole magnesium (test)
Fig. 5: Calibration curve of omeprazole magnesium
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Table 5: Absorbance of omeprazole magnesium






*Average of three readings
In vitro drug release study
The dissolution profile is presented in Table 8 given below. The rate 
release profile was plotted as the percentage linear drug release versus 
time. This showed that drug releases increases with increase in time. 
The dissolution data obtained were plotted as cumulative percentage 
release versus time.
It was observed that F3 and F6 showed higher release and both were 
again reformulated and evaluated in the similar manner and it was 
found that F6 was better in terms of drug release and stability, so, it was 

























10 1 1 Complies
Fig. 7: Fourier-transform infrared spectrum of omeprazole 
magnesium (after 15 days)
Fig. 6: Fourier-transform infrared spectrum of omeprazole 
magnesium (immediate)
Fig. 9: Fourier-transform infrared spectrum of omeprazole 
magnesium with sodium alginate (after 15 days)
Fig. 8: Fourier-transform infrared spectrum of omeprazole 
magnesium with sodium alginate (immediate)
Fig. 10: Fourier-transform infrared spectrum of omeprazole 
magnesium with calcium carbonate (immediate)
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Table 8: Results of in vitro drug release study of all formulation
Time (min.) F1 F2 F3 F4 F5 F6 F7 F8 F9
5 3.96 6.48 3.60 0.72 0.36 9.00 5.04 6.12 7.56
10 11.18 11.56 9.74 3.96 3.24 11.21 7.59 10.11 11.20
15 15.20 13.42 17.35 12.62 10.82 13.79 10.87 15.21 16.10
30 20.69 18.53 19.97 17.01 14.84 18.91 13.81 17.45 18.73
45 23.68 21.88 24.04 22.14 20.68 23.33 17.13 20.43 22.44
60 28.49 28.12 29.57 24.06 23.68 25.98 20.46 24.50 25.44
90 35.49 33.67 34.05 27.08 27.05 30.08 29.57 27.88 32.06
120 38.56 39.61 43.24 31.18 30.79 37.09 32.25 32.35 36.56
150 42.37 42.35 44.92 34.59 33.84 42.33 39.27 37.20 42.16
180 46.92 48.34 48.40 39.46 37.27 48.32 48.12 41.01 44.19
240 48.62 50.76 58.02 48.32 48.27 50.74 53.43 44.47 48.75
300 51.76 51.76 61.22 53.98 52.49 58.93 55.88 48.67 56.93
360 55.28 54.91 65.87 60.03 59.97 65.73 58.70 54.33 63.72
420 59.53 59.53 70.18 66.11 65.70 71.49 62.25 58.58 68.38
480 66.69 68.13 73.08 69.71 71.45 74.39 66.19 63.94 73.79
540 71.73 75.33 77.79 74.40 74.36 79.11 70.50 68.24 82.11
600 76.43 77.89 82.52 77.32 79.07 82.05 75.56 74.00 87.95
660 83.31 82.27 88.72 83.49 86.34 87.53 81.72 78.00 90.94
720 94.56 91.34 97.11 89.34 91.84 98.79 89.71 87.05 94.30
Table 7: Physicochemical properties of all formulation
Formulation code Color Homogeneity pH Gelling capacity Floating time (h) Floating lag time (s) Drug content
F1 White + 8±0.5 + 10 8 94.03
F2 White ++ 8±0.5 ++ 11 11 92.04
F3 Off White ++ 8±0.5 +++ >12 6 97.30
F4 Off White + 8±0.5 ++ 9 8 96.10
F5 White ++ 8±0.5 + >12 7 97.10
F6 Off White ++ 8±0.5 +++ >12 6 98.20
F7 White + 8±0.5 ++ 10 8 93.60
F8 White ++ 8±0.5 ++ 11 9 93.40
F9 Off White ++ 8±0.5 + 11.5 10 92.50
Table 9: Result of drug content (in duplicates)
Formulation code Marketed Final
Drug content (%) 92.10 91.23 97.81 97.92
selected as the final formulation and compared with available marketed 
preparation.
Comparative study of final formulation and marketed formulation
Drug content: The drug content observed is as following in Table 9.
In vitro drug release
The percentage release versus time value observed for marketed and 
final formulation in duplicates are mentioned in Table 10.
Kinetic modeling
Model independent Methods: A simple model independent approach 
uses a difference factor (f1) and a similarity factor (f2) to compare 
dissolution profiles.
Similarity factor: The result was found to be 51.31. Thus, it complies 
with the standard value (Table 11).
Fig. 12: Zero order equation of final formulation
Fig. 11: Fourier-transform infrared spectrum of omeprazole 
magnesium with calcium carbonate (after 15 days)
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Table 10: Results of in vitro drug release for final and marketed formulation
Time (min) 5 10 15 30 45 60 120 180 240 300 360 480 600 720
Final formulation (%CDR) 3.7 11.94 15.96 19.65 23.31 26.79 37.91 49.88 56.27 59.81 68.05 75.29 82.96 98.63
3.76 11.93 14.88 19.64 24.79 26.73 37.84 49.80 55.47 59.73 67.25 75.20 82.87 97.82
Marketed (%CDR) 2.91 10.4 24.9 43.1 67.8 89.7
3.28 10.9 26.2 43.8 69.12 90.12
Fig. 14: Higuchi equation of final formulation
Fig. 13: First order equation of final formulation
Fig. 15: Korsmeyer–peppas equation of final formulation Fig. 18: Higuchi equation of marketed formulation
Fig. 17: First order equation of marketed formulation
Fig. 16: Zero order equation of marketed formulation
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Table 13: Release kinetics of final formulation
Time 
(min)
Sq.rt time Log time %cdr log %cdr log % cdr 
remaining
5 2.2361 0.6990 9.63 0.9836 1.9560
10 3.1623 1.0000 11.94 1.0770 1.9448
15 3.8730 1.1761 15.96 1.2030 1.9245
30 5.4772 1.4771 19.65 1.2934 1.9050
45 6.7082 1.6532 23.31 1.3675 1.8847
60 7.7460 1.7782 26.79 1.4280 1.8646
120 10.9545 2.0792 37.91 1.5788 1.7930
180 13.4164 2.2553 49.88 1.6979 1.7000
240 15.4919 2.3802 56.27 1.7503 1.6408
300 17.3205 2.4771 59.81 1.7768 1.6041
360 18.9737 2.5563 68.05 1.8328 1.5045
480 21.9089 2.6812 75.29 1.8767 1.3929
600 24.4949 2.7782 82.96 1.9189 1.2315
720 26.8328 2.8573 98.63 1.9940 0.1367
Table 14: Release kinetics of marketed formulation
Time 
(min)
Sq.rt time log time %cdr log % cdr log %cdr 
remaining
5 2.2361 0.6990 3.28 0.5159 1.9855
10 3.1623 1.0000 10.9 1.0374 1.9499
15 3.8730 1.1761 26.2 1.4183 1.8681
30 5.4772 1.4771 43.8 1.6415 1.7497
45 6.7082 1.6532 69.12 1.8396 1.4897
60 7.7460 1.7782 90.12 1.9548 0.9948
Table 11: Results of similarity factor
Time (min) Test Reference Reference – Test log [{1+(Rt-Tt)*1/n}-0.5]*100 50+log [{1+(Rt-Tt)*1/n}-0.5]
5 3.7 3.28 −0.42 1.5569 51.5569
10 11.94 10.9 −1.04 1.9826 51.9826
15 15.96 26.2 10.24 1.5213 51.5213
30 19.65 43.8 24.15 1.1693 51.1693
45 23.31 69.12 45.81 0.8947 50.8947
60 26.79 90.12 63.33 0.7547 50.7547
Average 51.31
Table 12: Results of difference factor




5 3.28 3.7 −0.42 3.28 −1.1280 −112.8049
10 10.9 11.94 −1.46 14.18 −0.1030 −10.2962
15 26.2 15.96 9.2 37.1 0.2480 24.7978
30 43.8 19.65 34.39 70 0.4913 49.1286
45 69.12 23.31 69.96 112.92 0.6196 61.9554
60 90.12 26.79 109.14 159.24 0.6854 68.5381
Average 13.55
Difference factor
It was found to be 13.55. Thus, it complies with the standard value 
(Table 12).
Model dependent methods
The dissolution profiles were evaluated depending on the derived 
model parameters. The model dependent approach included zero 
order, first order, Higuchi, and Korsmeyer–Peppas model, etc.
Release kinetics
Release kinetics described the overall release of the drug from the 
dosage forms. Release kinetics of both final formulation and marketed 
product was determined using different mathematical models as 
shown in Tables 13 and 14. In case of zero order (Qt =  Qo+Kot). The graph 
was plotted in cumulative percentage release versus time and in first 
order release kinetic (log C= log Co – Kt/2.303). The graph was plotted in 
log cumulative percentage of drug remaining versus time. For Higuchi 
model kinetics (Q =  KH × t ½), the graph was plotted in cumulative 
percentage of drug versus square root of time and for the Korsmeyer-
Peppas (Q/Qo =  Ktn) model, the graph was plotted in log cumulative 
percentage of drug released versus log time.
These are graphically enlisted below (Figs. 5-19):
1. Final formulation
•	 Zero order equation




•	 Zero order equation
•	 First order equation
•	 Higuchi equation
•	 Korsmeyer-Peppas equation
Fig. 19: Korsmeyer–Peppas equation of marketed formulation
Table 15: R2 values of different models for final formulation and 
marketed formulation
Formulation Model R2 value
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Final formulation complies with marketed formulation for its release 
pattern, that is, Higuchi equation (Table 15).
CONCLUSION
The present work was carried out to develop a novel gel based in situ 
drug delivery system of omeprazole magnesium. The methodology 
adopted for preparation of in situ gel solution was very simple and cost 
effective. It is newer approach to improve easy instillation, residence 
time and bioavailability and prolong drug release. Nine formulation 
batches were prepared and subjected for evaluation, namely, floating 
lag time and in vitro drug release. Results showed that F3 and F6 gave 
good results for in vitro drug release and floating lag time. Among all 
the formulation, the F3 and F6 were best formulations. From these two 
formulations, the best was selected on the behalf of their respective 
evaluation parameter. F3 and F6 formulations were again formulated 
and evaluated. Results showed that F6 formulation gives best results. So, 
F6 was found to be the best candidate for further study. F6 formulation 
was evaluated for all parameters, namely, homogeneity, pH, color, 
floating lag time, floating time, in vitro drug release, and drug content. 
All the parameters were found to be within the limits. F6 formulation 
was then compared with the available marketed formulation, that is, 
OMEZ Insta 20 mg by Dr. Reddy’s. Comparison was made in respects, 
that is, drug content, in vitro drug release. Kinetic modeling was done 
between both the formulations with respect to model dependent 
and model independent kinetics. Final formulation complies with 
marketed formulation for its release pattern, that is, Higuchi equation. 
Results showed that in situ gel has good floating lag time and floating 
time that is an essential factor for in situ gel. In vitro drug release was 
found optimum. The f1 value was 13.55 (similarity or equivalence 
of two profiles) and f2 value was 51.31 (dissolution profiles are 
somewhat identical). The developed formulation is a viable alternative 
conventional solution by virtue of its ability to enhance bioavailability 
through its longer gastric residence time and ability to sustain drug 
release as well as the advantage of floating and pH which minimize the 
degradation of omeprazole magnesium which is easily degraded by 
acidic environment.
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